PureTech Affiliate Sonde Adds Thai Lee to Board

RNS Number : 8169M

PureTech Health PLC

02 May 2018

 

2 May 2018

PureTech Health plc

PureTech Health Affiliate Sonde Adds Thai Lee to Board of Directors

Appointment brings extensive business growth experience to affiliate's Board of Directors

PureTech Health plc (LSE: PRTC) ("PureTech Health" or the "Company"), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Sonde Health, an affiliate of PureTech Health, today announced the appointment of Thai Lee to its Board of Directors. Ms Lee is recognised as a prominent business leader in the information technology industry and brings more than two decades of experience to Sonde's Board of Directors. Ms Lee currently serves as President and Chief Executive Officer of SHI International Corporation. Under Ms Lee's management, SHI has transformed from a $1 million software reseller to a $10 billion in annual sales global provider of information technology products and solutions with 35 offices around the world. Ms Lee serves on the Board of Dean's Advisors at Harvard Business School and is a Life Trustee at Amherst College.

Eric Elenko, PhD, Chief of Research and Strategy at PureTech Health, said: "We are excited for Thai to be joining the Sonde Board of Directors. Her expertise and proven track record of success in information technology will be valuable as we scale up and grow our vocal biomarker platform for the detection, assessment, and treatment of high-burden health conditions."

The full announcement from Sonde is as follows:

Sonde Health Appoints Thai Lee to Board of Directors

Appointment brings valuable leadership and expertise in growing information technology businesses

BOSTON, Massachusetts, May 2, 2018-Sonde Health Inc., an affiliate of PureTech Health (PureTech Health plc, PRTC.L) developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced that Thai Lee, President and Chief Executive Officer of SHI International Corporation, has joined Sonde's Board of Directors. Ms Lee brings a wealth of experience in building and scaling-up one of the largest information technology solutions companies in the world, with $10 billion of annual sales.

"We are excited to welcome Thai to the Board of Directors of Sonde Health as the team advances this leading vocal biomarker technology platform," said Joi Ito, Chairman of the Board of PureTech Health & Director of the MIT Media Lab. "Thai will contribute her enormous experience to further unlock the power of voice as a platform for detecting physical and mental health conditions."

Ms Lee said, "By leveraging machine learning to derive valuable health information from billions of daily voice interactions while maintaining privacy and security, I believe Sonde's technology is well-suited to meet the high demand for innovative solutions that improve the early recognition and treatment of high-burden health conditions. I am enthusiastic to be joining Sonde's Board of Directors and working with this creative and dynamic team."

Ms Lee is the co-founder of SHI International Corporation, where she currently serves as President and Chief Executive Officer. SHI International is a global provider of information technology products and solutions. Under Ms Lee's leadership, SHI has transformed from a $1 million software reseller into a $10 billion in annual sales global provider of information technology products and solutions with 35 offices around the world. Previously, Ms Lee was involved in brand management for Procter & Gamble.

Ms Lee serves on the Board of Dean's Advisors at Harvard Business School, as Vice Chair of Harvard University's Campaign Executive Committee, and is a Life Trustee at Amherst College. She has been recognised as a top leader and innovator in information technology. In 2012, she was named Ernst & Young's Entrepreneur of The Year, and in 2013, she received the Harvard Business School's Alumni Achievement Award for distinguished graduates who have contributed significantly to their companies and communities. Ms Lee holds a BA in Economics and Biology from Amherst College and an MBA in General Management and Leadership from Harvard Business School.

"Thai's contributions will greatly enhance our ability to realise the extraordinary promise of our vocal biomarker technology," said Jim Harper, co-founder and Chief Operating Officer of Sonde Health. "Sonde's vision is to seamlessly turn voice commands to phones and speakers into snapshots of speaker health that catalyse numerous opportunities to partner and improve health and healthcare experiences. To do so, we are building out and scaling Sonde's platform and information services with unwavering focus on service, quality, value, and security.  Thai's incredible successes at SHI demonstrate her ability to build and lead diverse teams that consistently deliver across these key domains, and I am grateful she has agreed to join us."

About Sonde Health

Sonde Health, an affiliate of PureTech Health (PureTech Health plc, PRTC.L) is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions. Sonde's proprietary technology works by sensing and analysing subtle changes in the voice to create a range of persistent brain, muscle, and respiratory health measurements that provide a more complete picture of health in just seconds. To date, Sonde has collected voice data from over 3,000 subjects as part of the ongoing validation of its platform, and it has also initiated research and development to expand its proprietary technology into Alzheimer's, respiratory, and cardiovascular disease, as well as other health and wellness conditions. Sonde's Vocal Biomarker programme has demonstrated the potential to effectively screen and monitor for disease using information obtained from an individual's voice on commonly-owned devices and it has the potential to fundamentally change the way mental and physical health is monitored and diagnosed.

About PureTech Health

PureTech Health (PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the "BIG" axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, PureTech Health is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programmes, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech's research and development pipeline has been advanced in collaboration with some of the world's leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investors	EU media	US media
Allison Mead Talbot [phone] [e-mail]	Ben Atwell, Rob Winder [phone] [e-mail]	Tom Donovan [phone] [e-mail]

 

END

 

 

NRABIGDUIUGBGIB